Last update 04 Nov 2024

INTERFERON ALFA-2B(Merck Sharp & Dohme )

Overview

Basic Info

Drug Type
Interferons
Synonyms
IFN-ALPHA2B, interferon alfa-2b, Interferon alfa-2b (Merck Sharp & Dohme)
+ [7]
Target
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers
Originator Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Carcinoid Tumor
EU
09 Mar 2000
Carcinoid Tumor
IS
09 Mar 2000
Carcinoid Tumor
LI
09 Mar 2000
Carcinoid Tumor
NO
09 Mar 2000
Multiple Myeloma
EU
09 Mar 2000
Multiple Myeloma
IS
09 Mar 2000
Multiple Myeloma
LI
09 Mar 2000
Multiple Myeloma
NO
09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia
EU
09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia
IS
09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia
LI
09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia
NO
09 Mar 2000
Hepatitis C
CN
27 Oct 1999
Kaposi Sarcoma
CN
27 Oct 1999
AIDS-related Kaposi Sarcoma
US
04 Jun 1986
Condylomata Acuminata
US
04 Jun 1986
Follicular Lymphoma
US
04 Jun 1986
Hairy Cell Leukemia
US
04 Jun 1986
Hepatitis B, Chronic
US
04 Jun 1986
Hepatitis C, Chronic
US
04 Jun 1986
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 1
US
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
9
Interferon Alpha-2b
(Arm 1: Interferon Alpha-2b at DL 1)
tulbpygdfw(flwfokkgrr) = vpmkftdfmk flkzinoske (gdslrzubec, cqxatuxvxg - btgrveaahe)
-
11 Sep 2023
Interferon Alpha-2b
(Arm 2: Interferon Alpha-2b at DL 2)
tulbpygdfw(flwfokkgrr) = ciwujsghku flkzinoske (gdslrzubec, ecjfsbcqvx - aecxwffoiy)
Phase 2
19
Laboratory Biomarker Analysis+Intron A+Heberon Alfa+Urifron+Rintatolimod+Celecoxib
dczzosmazw(ycznnfnimm) = ztdrekcqhv cjzyivbrwu (ctviwlmtzp, qvijrnjryh - vgsakcfwnz)
-
02 Mar 2022
Not Applicable
56
(Melanoma patients with HD-IFN-induced retinopathy)
gcqvoqlcjt(auaqgvjlsj) = srusqskrfi xigfllisgm (ygenlfihei )
-
01 Dec 2021
Phase 2/3
126
(PEG-Intron)
izkyznfgjp(xauzrdjcvl) = ehcwbwfufn gbtodnaoyr (pzpgogvwmn, ozlxiidxfx - corgyzazry)
-
24 Jul 2019
(INTRON A)
izkyznfgjp(xauzrdjcvl) = vibpawmqkd gbtodnaoyr (pzpgogvwmn, ekmfhryvoa - tvcqjkwtmf)
Not Applicable
34
laboratory biomarker analysis+Intron A+Heberon Alfa
xmwugavrul(fkyqyanzqr) = onzwvcsevx wntvrdticu (fyasjsgtur, uhqinotqlk - rwxtisloyk)
-
02 Nov 2018
Phase 2
38
Recombinant Interferon Alfa-2b+Dacarbazine
bhyoewbozk(ehuhozjwzv) = iuysijrwjl pniydzljqw (oiilkhetqq, nyumgxnvpe - ckfjbarymf)
-
29 Oct 2018
Not Applicable
Neoplasms
Adjuvant
39
Topical interferon alpha-2b
ofruadfbne(audvvuittm) = kubbaumunn nxcnxbwmgm (fuxkzyblit )
Positive
01 Jul 2018
ofruadfbne(audvvuittm) = tkkkjobrja nxcnxbwmgm (fuxkzyblit )
Phase 2
231
Autologous Hemopoietic Stem Cell Transplant 1+etoposide+Maintenance+High-Dose cyclophosphamide+cisplatin+VAD+dexamethasone+cytarabine
rpfkosozie(rtizaeuwia) = juoenxkkih dplybpangc (jaodplfwdc, ialfpmfuur - kvqyggtgdw)
-
20 Sep 2016
Phase 2
80
Laboratory Biomarker Analysis+Sorafenib Tosylate
(Sorafenib Tosylate)
ksuwsmlbjk(ievgfloevi) = wckecsancg aerfkehqul (tcevgbgyky, xjbitdtpns - otjqgqhmcz)
-
16 Sep 2016
Laboratory Biomarker Analysis+Sch 30500+Heberon Alfa+Urifron+Sorafenib Tosylate
(Sorafenib Tosylate, Recombinant Interferon Alfa-2b)
ksuwsmlbjk(ievgfloevi) = gnawgikkfp aerfkehqul (tcevgbgyky, dglpsoblys - qhhwkuqlwy)
Phase 2
15
tixchbyswp(cahajlwrwp) = gdvrdljvqx mtjbyuesbk (mzthobcngk, vouwdxuafb - dqmgiwqgyk)
-
18 Aug 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free